- 作者：Kentaro Okuda ; M.D. ; Naozumi Takeshima ; M.D. ; Ph.D. ; Satoshi Hagiwara ; M.D. ; Ph.D. ; saku@oita-u.ac.jp ; Junji Takatani ; M.D. ; Tetsuya Uchino ; M.D. ; Takayuki Noguchi ; M.D. ; Ph.D.
- 关键词：anthranilic acid ; Freund&rsquo ; s complete adjuvant (FCA) ; pain ; iNOS ; PAR2
- 刊名：Journal of Surgical Research
- 出版年：2012
- 出版时间：15 June, 2012
- 年：2012
- 卷：175
- 期：2
- 页码：265-270
- 全文大小：573 K
Background
Acute and chronic pain commonly accompany various clinical conditions such as contusion, fracture, osteoarthritis, peripheral neuropathy, and postherpetic neuralgia. Recent studies have found that antioxidative drugs can have analgesic effects. The present study tested the hypothesis that a new anthranilic acid derivative, EAntS-GS, exerts antinociceptive effects on inflammatory pain in a rat model.Methods
We induced subacute pain with a plantar injection of Freund¡¯s complete adjuvant (FCA) in Sprague-Dawley rats. EAntS-GS (1 mg/kg subcutaneous injection or 1 % application) was administered every 12 h beginning 24 h after FCA administration, and the plantar test was used to determine its effect on pain. Levels of myeloperoxidase, inducible nitric oxide synthase (iNOS), and protease activated receptor 2 (PAR2) were measured to elucidate the mechanism of action of EAntS-GS.
Results
EAntS-GS significantly reduced FCA-induced pain and myeloperoxidase, iNOS, and PAR2 levels. Our findings suggest that the new anthranilic acid derivative, EAntS-GS, exerts antinociceptive effects, and that the mechanism involves iNOS and PAR2.
Conclusion
We conclude that EAntS-GS should be considered a new therapeutic tool to treat acute and chronic pain.